Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irradiated donor-derived CD19-zeta-transduced EBV-lymphoblastoid cell line
- Development stage
- Unknown
- Lead developer
- University College London
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Subcutaneous
01
Overview
Irradiated donor-derived CD19-zeta-transduced EBV-lymphoblastoid cell line is a cellular immunotherapy developed by University College London for the treatment of high-risk or relapsed B-cell acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation. The product consists of lymphoblastoid cell lines (LCLs) generated from the stem cell donor by infecting B-cells with Epstein-Barr Virus (EBV). These LCLs are genetically modified with a retroviral vector (SFGalpha-CD19-CD3zeta) to express a CD19-specific chimeric antigen receptor (CAR) and are subsequently irradiated (typically at 70Gy) to render them non-proliferative while maintaining their antigenicity. Administered subcutaneously, these cells function as a cellular vaccine designed to provide antigenic stimulation to infused CD19-zeta gene-modified EBV-specific cytotoxic T-lymphocytes (CTLs), thereby promoting their expansion and long-term persistence in vivo.
- Other names
- CD19-zeta-transduced EBV-LCLCD-19-zeta-transduced EBV-LCLCD 19-zeta-transduced EBV-LCLIrradiated donor-derived EBV-LCLIrradiated donor-derived Lymphoblastoid Cell Line
02
Targets
Beyond the preview
Go deeper on Irradiated donor-derived CD19-zeta-transduced EBV-lymphoblastoid cell line.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irradiated donor-derived CD19-zeta-transduced EBV-lymphoblastoid cell line.